⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BTAI News
BioXcel Therapeutics, Inc. Common Stock
Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer
prnewswire.com
BTAI
Form 8-K
sec.gov
BTAI
METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
prnewswire.com
BTAI
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
prnewswire.com
ADCT
BTAI
RLAY
Local Orthopedic Surgeon First in Area to Use New Treatment Option for Complex Shoulder Surgery
prnewswire.com
BTAI
China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy
prnewswire.com
BTAI
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
globenewswire.com
BTAI
BioAge Labs to Present at Upcoming Investor Conferences
globenewswire.com
BIOA
BTAI
Form 8-K
sec.gov
BTAI
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
globenewswire.com
BTAI